Statement of Principles concerning renal stone disease (Reasonable Hypothesis) (No. 69 of 2019)

The instrument rests on several discrete legal and medical concepts set out in the operative text and the Schedule 1 dictionary. First, the legal standard: the Statement is framed to address when a "reasonable hypothesis" has been raised connecting the condition to relevant service. Section 9 prescribes that at least one of the listed factors must exist before that threshold is met. The instrument does not itself restate the statutory definition of "reasonable hypothesis"; rather it provides the factors that, if proved, fulfil the relevant claims standard in VEA s120A or MRCA s338 because the instrument applies to claims under those sections (s5).

Second, the medical definition of the condition. Renal stone disease is defined narrowly: calculi in the kidney (nephrolithiasis) or ureter (ureterolithiasis) arising from crystallisation of mineral salts in urine. The definition excludes nephrocalcinosis and primary lower urinary tract calculi (s7(2)). Although renal stone disease normally attracts ICD‑10‑AM code N20, the instrument instructs that for its purposes the statutory textual definition in s7(2) controls (s7(3)-(4)). Death from renal stone disease is included if the terminal event or condition was contributed to by the person’s renal stone disease, where "terminal event" is defined in the Schedule (s7(5); Schedule).

Third, a catalogue of causative or predisposing factors. Section 9 lists 29 separate factors, ranging from very specific (being a prisoner of war of the Japanese before clinical onset, s9(1)) to clinical diagnoses (primary hyperparathyroidism within 10 years prior to clinical onset, s9(2); post‑surgical hypoparathyroidism at onset, s9(3); gout or hyperuricaemia at onset, s9(6)), to drug exposures (treatment with a drug from a specified list within six weeks prior to onset, s9(16); the specified list is in Schedule 1), to surgical procedures (malabsorptive bariatric procedure, ileal resection or Roux‑en‑Y in the five years prior to onset, s9(14)), to occupational and environmental exposures (inhaling cadmium fumes for a cumulative period of at least 3 500 hours with onset within ten years of cessation, s9(27)), to very specific events (spaceflight continuous period of at least seven days within the 30 days before onset, s9(28)), and lifestyle or physiological thresholds (being overweight or obese for five years preceding onset, s9(24); inadequate fluid intake as per Schedule, s9(23)).

Fourth, temporal and quantitative thresholds. Many factors specify precise look‑back windows or objective numeric thresholds which must be satisfied. Examples: primary hyperparathyroidism within ten years prior to clinical onset (s9(2)); drug treatment within six weeks prior to onset (s9(16)); malabsorptive bariatric procedures within five years (s9(14)); vitamin D combined with at least 1 000 milligrams calcium daily for a continuous two years before onset (s9(17)); inadequate fluid intake defined as urine volume less than 750 mL on average daily or urine consistently darker than a pale yellow for a defined period (Schedule, definitions). These thresholds set evidentiary boundaries for claims.

Fifth, incorporation and interdependence with other Statements of Principles. If any factor in s9 refers to an injury or disease that itself is covered by another Statement made under subsection 196B(2) of the VEA, then that other Statement applies in accordance with its own terms as in force (s11). This creates a networked evidentiary regime where comorbid diseases governed by separate Statements can supplant or supplement the causal analysis.

Finally, relational requirement to service. The instrument repeatedly requires that the identified factor must be related to the person’s relevant service as defined in the Schedule (s10(1)). The definition of relevant service mirrors categories under the VEA and MRCA (operational, peacekeeping, hazardous, British nuclear test defence service; warlike and non-warlike under MRCA) and therefore ties the medical factors to statutory service categories (Schedule).

These concepts collectively transform medical facts into administrable evidentiary thresholds used in the determination of liability in VEA and MRCA claims. The instrument supplies precise language and thresholds; claimants and decision makers must assess medical records, exposures and timing against those particulars.

This Statement is an instrument designed for use in the VEA and MRCA claims systems. It applies expressly to claims to which section 120A of the Veterans' Entitlements Act 1986 or section 338 of the Military Rehabilitation and Compensation Act 2004 apply (s5). The Schedule defines "relevant service" to include operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA. That means the population directly affected is serving or former members of the Australian Defence Force (and certain other classes such as members of Peacekeeping Forces) who make claims under the VEA or MRCA and who have renal stone disease or died from renal stone disease where a legal causation question with respect to service exists.

Who bears the evidentiary burden in practice? The Statement sets out the medical factors that, if established and related to relevant service, will raise a reasonable hypothesis of service connection (s9, s10). For claimants and their advisers, this is the list to consult when assembling evidence. For decision makers in the Department or tribunal processes, this Statement is the measuring stick for when a reasonable hypothesis exists. The Statement does not create criminal liability or civil sanctions; its effect is administrative and procedural within the statutory compensation and benefits systems outlined in the VEA and MRCA.

The Statement also affects clinicians and medical practitioners who prepare certificates and reports for claims. The defined thresholds require medical evidence of specific diagnoses, lab values, documented periods of immobility, surgical histories, drug exposures with dates, occupational exposure records (for example cumulative cadmium exposure hours), and operative notes for urinary diversion or bariatric procedures. For example, a treating physician must be able to document primary hyperparathyroidism within ten years before clinical onset, or that the patient used a vitamin D supplement combined with at least 1 000 milligrams of calcium daily for two continuous years before onset (s9(2), s9(17)).

Secondary effects reach administrative agencies deciding entitlements, because s11 creates dependencies on other Statements of Principles: where a factor in s9 refers to a disease already covered by another Statement, that other Statement governs the application of the factor (s11). Thus the instrument may shift evidentiary burdens between connected claim streams.

Specific classes are identified in the factors themselves. For instance, being a prisoner of war of the Japanese before clinical onset explicitly appears as a factor (s9(1)). Occupational exposure to cadmium is quantified and requires records of soldering, welding, smelting work or plant employment that produced a cumulative exposure of at least 3 500 hours with onset within 10 years of cessation (s9(27)). Spaceflight of at least seven continuous days within 30 days before clinical onset is a discrete, high‑specificity factor (s9(28)). Those groups, although numerically small, are directly targeted by specific factors.

Finally, claimants whose renal stone disease interacts with other medical conditions should be aware that if a s9 factor refers to a condition governed by another Statement, the rules and thresholds in that other Statement apply (s11). This is particularly relevant for complex comorbidities where multiple Statements may need to be consulted.

The instrument itself does not create positive duties in the sense of enforcement or criminal penalties. Instead it imposes procedural obligations and evidentiary expectations within the VEA and MRCA claims framework. The primary operative duties or obligations flow from the text and can be grouped as duties of proof, temporal relation, and cross‑reference obligations.

Duty of proof of at least one factor: A claimant seeking to establish a reasonable hypothesis that renal stone disease or death from renal stone disease is connected to service must demonstrate the existence of at least one of the factors in s9. Section 9 opens with the rule that "At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised" (s9). In practice this is an evidentiary duty to adduce medical records, exposure documentation and other records that satisfy the relevant factor's conditions.

Duty to relate the factor to service: Section 10 mandates that any factor relied upon must be related to the relevant service rendered by the person; it is not sufficient to show a factor existed unconnected to service (s10(1)). Practitioners and claimants must therefore establish the causal or temporal connection between service and the factor. For example, proving cadmium exposure (s9(27)) will also require proof that the exposure occurred in the course of relevant service or that the service materially contributed to that exposure.

Special limitation on factor 29: Subsection 10(2) restricts how s9(29) (inability to obtain appropriate clinical management) operates. It applies only to material contribution to, or aggravation of, renal stone disease where the disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service. In other words, the inability to obtain appropriate clinical management is not a standalone factor to establish that the disease arose out of service; it is only a basis for material contribution or aggravation where a prior disease existed (s10(2)).

Duty to follow cross‑referenced Statements: If a s9 factor refers to an injury or disease for which there is another Statement of Principles, subsection 11(1)-(2) requires that the factors in that other Statement apply according to their terms (s11). This imposes an obligation on decision makers and claimants to consult and apply other Statements where appropriate, rather than treat s9 as exclusive.

Rights: The primary right created or supported by the instrument is the claimant’s right to rely on an authoritative, written list of factors that constitute a reasonable hypothesis for service connection. The Statement supplies predictable, defined thresholds and time windows which claimants can seek to satisfy with evidence. It also benefits the administrative decision maker by providing a uniform standard for adjudication across VEA and MRCA claim processes.

Limits on rights and duties: The Statement is an evidentiary tool rather than an adjudicative determination. It neither entitles an applicant automatically to compensation nor substitutes for the statutory grants and procedural rules in the VEA or MRCA. The Statement simply identifies what medical and exposure facts will be sufficient to raise a reasonable hypothesis under the statutory framework to which it applies (s5, s9).

No penal or enforcement rights: There are no provisions in the instrument creating penalties for non‑compliance by claimants or others, nor does the Statement create enforcement mechanisms. The consequences are administrative: if a factor in s9 is established and related to service, that will be a relevant input for decisions under the VEA or MRCA.

Documentation duties implied by the text: Because several factors depend on quantitative measures and specific windows (for example serum uric acid levels, durations of immobility, cumulative hours of cadmium exposure, continuous periods of drug use), there is an implicit duty on medical practitioners and claimants to ensure that the records presented document these thresholds. The Schedule provides precise definitions for terms like "inadequate fluid intake", "being overweight or obese" (BMI 25 or greater), "hyperuricaemia" (serum uric acid at least 6.8 mg/dL) and others; those numerical definitions are the standards by which evidence will be judged.

In sum, the instrument allocates evidentiary duties to claimants and documentation/assessment duties to medical advisers and decision makers, while conferring the right to rely on its specified factors in determining whether a reasonable hypothesis of service connection exists.

The Statement contains no penal provisions, fines, or criminal sanctions. It is an administrative instrument made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s3) and operates as guidance and a binding set of factors for assessing whether a reasonable hypothesis exists in the statutory claims processes governed by the VEA and MRCA (s5, s9). The text of the instrument does not provide for enforcement mechanisms in the criminal law sense. It does not authorize investigatory powers, require reporting to regulatory bodies, or establish administrative penalties for non‑compliance with the Statement itself.

Enforcement in practice is administrative and indirect. The Statement’s practical force arises because entitlement decisions under VEA s120A or MRCA s338 will be informed by whether a claimant can establish at least one factor from s9 and its relationship to relevant service under s10. If a claimant cannot establish the requisite factor, a decision maker could reject a claim for service connection. Conversely, if at least one factor is established and related to service, the decision maker may find that a reasonable hypothesis exists, which in turn can produce favourable outcomes such as acceptance of service connection and access to benefits and treatment under the VEA or MRCA. The instrument does not itself state this chain of administrative consequence; this is the operative context because the Statement applies to claims under the specified statutory sections (s5).

There is no provision for sanctions against health professionals who give incorrect statements, or for claimants who provide false information, in this instrument. Any such consequences would arise under other laws or administrative procedures outside the instrument’s text. Likewise the Statement does not prescribe remedies or reversal procedures; appeal and review routes will be those built into the VEA and MRCA statutory frameworks rather than this instrument.

Compliance checking rests with the decision making bodies and their adjudicators, who will determine whether medical records, occupational histories, lab tests and other evidence meet the precise definitions and thresholds given in the Schedule and s9. For example, a decision maker will verify serum uric acid levels against the Schedule definition of hyperuricaemia (at least 6.8 mg/dL) or check cumulative cadmium exposure hours (3 500 hours) against employment records (s9(27); Schedule). Failure to meet a stipulated threshold is not penalised by the Statement but will likely result in the claim failing to meet the reasonable hypothesis threshold.

In short, the Statement creates no enforcement penalties but creates administrative consequences for claims, by setting clear conditions for the existence of a reasonable hypothesis connecting renal stone disease or death from it to relevant service.

The Statement is an instrument made under the VEA and expressly designed to operate within that statutory ecosystem and the MRCA ecosystem. Its interactions with other laws are defined in the instrument itself.

Primary statutory interface: The Statement applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). Those statutory provisions are the decision points at which the Statement’s factors are invoked. The instrument does not amend the VEA or MRCA; it supplements the statutory standards by providing medical factors that evidence a "reasonable hypothesis" of service connection for a particular disease.

Incorporation and cross‑reference to other Statements: Subsection 11 provides that where a factor in s9 refers to an injury or disease that is itself the subject of another Statement determined under subsection 196B(2) of the VEA, the factors in that other Statement apply according to their terms as in force from time to time (s11). This mechanism creates a network of Statements where diseases and injuries that interact (for example, haematological diseases, systemic diseases, or other conditions which may both predispose to renal stones and be separately covered by other Statements) must be considered under their own governing texts. Decision makers must therefore consult the full set of relevant Statements and apply those terms rather than attempt to re‑characterise or re‑define the related disease.

Use of ICD‑10‑AM code: Section 7(3) and (4) state that while renal stone disease attracts ICD‑10‑AM code N20, for the purposes of the Statement the meaning in s7(2) controls; the instrument also identifies the tenth edition ICD‑10‑AM effective 1 July 2017 with its ISBN, specifying the reference point for coding (s7(3)-(4)). This aligns the instrument with international classification practice but preserves the instrument’s textual definition as authoritative.

Interaction with clinical and statutory definitions: The Schedule defines terms such as hyperuricaemia numerically (serum uric acid 6.8 mg/dL or greater), BMI thresholds (BMI 25 or greater), definitions of inadequate fluid intake (urine volume thresholds or consistent urine colour criteria), and the definition of terminal event. These definitions interact with medical record evidence and may overlap with definitions used in other medical contexts or laws. Where a term or disease appears as a factor and is also covered in another Statement, s11 directs that the other Statement’s factors apply.

Implications for administrative law and review: The instrument supplies evidence thresholds which are likely to be treated as authoritative by administrative decision makers. Its role is evidentiary rather than adjudicative; appeals or merits review from decisions that apply the Statement will occur under the VEA and MRCA administrative law pathways. The Statement does not alter procedural rights of review or merits review but will be cited as the controlling medical standard in dispute.

No interaction with criminal or workplace safety law in the instrument: The Statement references occupational exposures such as cadmium inhalation (s9(27)), but it does not create workplace obligations, compensation schemes outside the VEA/MRCA framework, or regulatory offences. Any interaction with workplace health and safety laws, workers compensation schemes, or criminal provisions governing negligent conduct must be handled outside this instrument.

Deadlines and commencement: The instrument repealed the previous Statement No. 65 of 2010 (s4) and commenced on 22 July 2019 (s2). For claims, decision makers must apply the Statement as it stands on commencement for matters within its temporal application, keeping in mind that s11 contemplates the other Statements' terms as "in force from time to time".

In short, the Statement interacts with the VEA and MRCA by feeding into their causation assessments, cross‑links with other Statements where diseases overlap, and uses clinical coding standards, but it does not create standalone statutory obligations or criminal/regulatory effects beyond the administrative claim consequences.

The instrument itself records a minimal amendment history in its operative text. It is identified as Statement of Principles concerning renal stone disease (Reasonable Hypothesis) (No. 69 of 2019) (s1). It commenced on 22 July 2019 (s2) and was made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s3). Importantly, subsection 4 provides that the Statement of Principles concerning renal stone disease No. 65 of 2010 (Federal Register of Legislation No. F2010L02304) is repealed (s4). That is the only repeal recorded in the document. There is no further amendment schedule, transitional provisions or savings clauses in the text supplied.

What the text does not record: the instrument does not include a schedule of amendments prior to No. 69 of 2019 except the direct repeal of No. 65 of 2010. It does not list interim amendments, consolidations of the Schedule, or subsequent variations. The instrument references other Statements of Principles in s11, and contemplates that those Statements apply "as in force from time to time"; that language creates an expectation of future amendments to those other Statements, but this instrument does not itself show later amendments.

Dates and formalities: The instrument is dated 21 June 2019 on its face and bears the Common Seal of the Repatriation Medical Authority (front matter). The instrument’s effective date is 22 July 2019 as the commencement date (s2). There is no express retrospective or transitional application provision in the text provided; readers should therefore assume the instrument applies from its commencement to claims as governed by the VEA and MRCA provisions in force after that date, subject to the ordinary principles of statutory application and any transitional rules imposed by the VEA or MRCA (none of which are in this instrument).

Recommendation for practice: Because the instrument replaced No. 65 of 2010, practitioners should check any decisions rendered between the repeal and the commencement date for transitional application. The instrument does not itself provide express transitional rules; a careful reading of the VEA/MRCA and administrative practice statements is required to determine which Statement applied to claims lodged or decided around the changeover.

In summary, the amendment history recorded in the instrument is limited to its own making, commencement and the express repeal of the 2010 Statement. The instrument does not record further historical amendments, and any later changes to this Statement would be found in subsequent instruments or in the Federal Register of Legislation rather than in this text.

The instrument contains no record of litigation history. There are no citations to cases, no mention of judicial interpretation, and no annexed decisions. The text is purely the Statement of Principles as determined by the Repatriation Medical Authority and does not report any court or tribunal outcomes applying this instrument.

As an administrative instrument used in the determination of benefits and compensation, its provisions may be subject to judicial review, merits review or appeal in particular cases under the VEA and MRCA frameworks. However, the Statement itself provides no summary or record of such litigation, and the instrument makes no reference to any judicial decisions interpreting its operation or the meaning of its clauses. If litigation or tribunal decisions exist that engage this Statement, they are not contained in the text provided.

For practitioners, that means one must look outside this instrument to locate any authorities that interpret or apply it. The instrument’s presence and wording will be relied upon in administrative decision making and, if contested, in merits review or judicial review proceedings arising out of VEA or MRCA decisions. Any such cases must be identified by independent legal research; none are set out here.

Where the instrument refers to other Statements of Principles (s11), there may be litigation concerning the interaction between Statements, the application of the "reasonable hypothesis" standard, or the evidentiary sufficiency of particular types of medical evidence. Again, the instrument does not summarise those authorities. Practitioners must therefore treat this section as stating a lack of litigation history within the document and proceed to consult case law databases and tribunal records for litigation applying the Statement in practice.

Finally, the absence of litigation history in the instrument does not mean that disputes will not arise. The precise temporal and quantitative thresholds set out in the Schedule and s9 (for example cadmium 3 500 cumulative hours, vitamin D plus at least 1 000 mg calcium daily for two years, BMI 25 or greater for five years) are the kinds of issues that commonly generate evidentiary disputes in claims. Practitioners should be prepared to marshal contemporaneous documentary evidence and expert medical evidence where these thresholds are in contention.

The Statement contains several technical particularities and potential pitfalls that practitioners must watch for when preparing or assessing claims. Many of these are literal features of the text and its Schedule definitions.

Literal exclusions: The instrument’s definition of renal stone disease expressly excludes nephrocalcinosis and primary calculus of the lower urinary tract (urinary bladder or urethra) (s7(2)(b)). A claimant whose imaging or clinical notes use broader language must ensure the pathology fits the s7(2) definition. Do not rely on ICD‑10‑AM code alone; s7(3)-(4) states the statutory textual definition controls over coding.

Precise and sometimes uncommon thresholds: Several factors impose precise numeric or temporal thresholds that must be met exactly as stated. Examples include:

• vitamin D supplement combined with at least 1 000 milligrams calcium daily for a continuous two years before clinical onset (s9(17));
• cumulative inhalation exposure to cadmium fumes for at least 3 500 hours, and where exposure has ceased the clinical onset must occur within ten years of cessation (s9(27));
• spaceflight for a continuous period of at least seven days within the 30 days before clinical onset (s9(28));
• being overweight or obese means BMI of 25 or greater and must have been so for at least five years prior to clinical onset (s9(24); Schedule).

Ambiguous or surprising numeric language: Section 9(22) states "an inability to consume an average of at least 400 grams of calcium per day for a continuous period of at least six months, within the one year before the clinical onset of renal stone disease." The instrument literally uses "400 grams of calcium per day". That is a large and physiologically implausible absolute quantity for elemental calcium compared to typical dietary or supplemental measures, and it stands out as an unusual formulation. The instrument’s text is definitive; any claimant or practitioner relying on s9(22) should note the literal wording and be prepared to address it in evidence. The Schedule does not further define "grams of calcium" or correct this figure. Practitioners should verify whether this is an artefact in the text or whether clinical evidence can sensibly be framed to meet this threshold.

Narrow scope of some factors: Factor 29 (inability to obtain appropriate clinical management) operates only in relation to material contribution to, or aggravation of, renal stone disease where the disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s10(2)). That means inability to obtain appropriate clinical management does not underpin a finding that the disease arose out of service; it can only be used in a limited way to show aggravation or contribution in pre‑existing disease. Claims that attempt to rely on clinical management failures as the initial cause need to meet this threshold.

Dependence on other Statements: Where a s9 factor refers to an injury or disease covered by another Statement, the other Statement applies as in force from time to time (s11). This can generate complexity where multiple Statements must be consulted; practitioners must identify and apply the currently operative wording of those other Statements.

Objective measures and evidentiary standards: Several definitions in the Schedule are strictly objective and may require specific tests. For example:

• hyperuricaemia is defined as serum uric acid at least 6.8 mg/dL (Schedule);
• inadequate fluid intake is defined partly by an average daily urine volume of less than 750 millilitres, or consistently darker than pale yellow on a standard chart (Schedule);
• distal renal tubular acidosis is tightly defined by a constellation of laboratory findings and clinical features (Schedule).

Claimants without contemporaneous tests, urine diaries, or occupational exposure records will struggle to meet these thresholds. Retrospective clinical assertions without documentary support may be insufficient.

Overlap and interaction with other diseases: Several s9 factors cite diseases that are themselves complex (e.g. haematological malignancy, sarcoidosis, Cushing syndrome, inflammatory bowel disease). Where those diseases are involved, s11 requires applying other Statements. Practitioners should not treat s9 as a stand‑alone list where other Statements are implicated.

Temporal counting: Many factors specify look‑back windows that require precise calculation from the date of clinical onset as defined by the instrument. Practitioners must establish the clinical onset date carefully; ambiguity about onset date can determine whether a factor falls within an applicable window. The instrument uses "clinical onset of renal stone disease" in s9 repeatedly without defining the exact method to determine that date; standard clinical definitions and contemporaneous records should be used.

Terminology that requires translation: Terms such as "being immobile" have a precise definition in the Schedule meaning gross diminution or near complete absence of movement (for example bed‑bound or paralysis). Descriptions like "reduced mobility" or "limited activity" in records may not meet the Schedule definition without clear clinical documentation.

Drug lists and narrow windows: The specified list of drugs is extensive and includes many common agents (for example quinolones, ceftriaxone, topiramate, triamterene, phenytoin, orlistat). The temporal window for drug exposure is six weeks before clinical onset (s9(16)). Practitioners must provide prescription records, dispensing history, hospital charts or similar to show the timing.

Finally, coding versus definition: While the instrument references ICD‑10‑AM code N20 as the usual classification (s7(3)), it unambiguously directs users to its textual definition in s7(2). Reliance on coding alone, without checking the statutory text and exclusions, is a recurring risk in claims assessment.

In practice the "gotchas" are therefore factual and evidentiary. The text sets specific, sometimes unexpected, tests and thresholds. Successful claims will hinge on precise documentation and tight alignment between medical records and the instrument’s exact language.

For claimants, clinicians and advisers preparing claims under the VEA or MRCA, compliance means assembling an evidentiary package that maps directly onto the factors and definitions in this Statement. The Statement is an evidentiary checklist: satisfy at least one factor in s9 and show it is related to relevant service as required by s10. Practical steps follow directly from the instrument’s clauses and Schedule definitions.

1. Identify the appropriate statutory claim route

• Confirm that the claim is one to which VEA s120A or MRCA s338 applies, because this Statement is applied to those claim types (s5). Ensure relevant procedural forms and time limits under the VEA or MRCA are observed.

2. Establish the clinical onset date

• Determine and document the date of clinical onset of renal stone disease. Many factors require calculating look‑back windows from the clinical onset. Use contemporaneous clinical notes, imaging dates, emergency presentations, or operative reports to fix the onset date.

3. Match evidentiary facts to one or more s9 factors

• Review s9 in detail and identify which factor(s) may be satisfied. For each candidate factor assemble evidence aligned to the factor’s specific requirements:
  • Clinical diagnoses: Provide specialist letters, laboratory results, histopathology, imaging, operative notes and discharge summaries for conditions such as primary hyperparathyroidism (s9(2)), hypoparathyroidism after surgery (s9(3)), haematological diseases (s9(5)), gout/hyperuricaemia (s9(6) with numeric definition in Schedule), distal renal tubular acidosis (s9(10) with Schedule criteria), and systemic diseases such as Cushing syndrome or sarcoidosis (s9(15); Schedule).
  • Surgical procedures and transplants: Provide operative reports and dates for malabsorptive bariatric procedures, ileal resections, Roux‑en‑Y, urinary diversion or renal transplant (s9(14), s9(18), s9(26)). Note the look‑back windows specified (for example five years for bariatric procedures).
  • Drug exposures: Provide prescription records, dispensing data or hospital medication charts showing drug names, dates and durations for agents in the specified list within six weeks before clinical onset (s9(16); Schedule).
  • Supplements and dietary intake: For vitamin D plus calcium supplementation (s9(17)), provide records showing supplement composition and dates to evidence at least 1 000 mg calcium daily for two continuous years. For inability to consume calcium (s9(22)), carefully document dietary histories, dietician reports, and any clinical reasons for dietary restriction; note the instrument’s literal wording of "400 grams of calcium per day" and be prepared to address it.
  • Hydration and urine volume: For inadequate fluid intake (s9(23) and Schedule), obtain urine volume records, outpatient fluid diaries, or clinical notes showing consistent urine colour equal to or darker than the chart grades specified. Where recorded urine volumes are absent, urine colour charts with contemporaneous clinical notes may be used but will be scrutinised.
  • Occupational exposures: For cadmium inhalation (s9(27)), obtain employer records, rosters, occupational hygiene reports, statutory exposure monitoring and wage sheets to demonstrate cumulative exposure hours (3 500 hours) and, if exposure ceased, that onset occurred within ten years of cessation.
  • Immobilisation and disability: For being immobile, paraplegia/quadriplegia or postoperative immobility (s9(20)-(21)), obtain hospital records, rehabilitation notes, mobility assessments and specialist reports documenting gross diminution or near absence of movement and time periods.
  • Spaceflight: For spaceflight (s9(28)), obtain mission logs, service records, certificates and dates demonstrating continuous period of at least seven days within 30 days prior to clinical onset.
  • Inability to obtain management: For inability to obtain appropriate management (s9(29)), document contemporaneous attempts to obtain treatment, denials, lack of access during service, and demonstrate that the disease was suffered or contracted before or during service and that inability to obtain management materially contributed to or aggravated the disease (s10(2)).

4. Demonstrate relationship to relevant service

• For each factor relied upon, prepare evidence linking the factor to the person’s relevant service as defined in the Schedule. This may include service medical records, duty rosters, deployment records, occupational role descriptions, and service health assessments.

5. Address exclusions and cross‑references

• Ensure that the condition being claimed fits the instrument’s definition of renal stone disease (s7(2)) and is not excluded (for example nephrocalcinosis). If a s9 factor refers to a disease covered by another Statement, obtain and apply that other Statement in force at the time (s11). This may require assembling evidence that satisfies the alternative Statement’s criteria.

6. Use defined numeric thresholds

• When the Schedule supplies numerical definitions (for example hyperuricaemia at least 6.8 mg/dL; BMI 25 or greater), present laboratory reports, weight/height records and calculations that satisfy those numbers. Provide the raw data so the decision maker can calculate BMI or serum levels.

7. Anticipate evidentiary challenges and prepare experts

• Be prepared to supply expert medical opinion that links the identified factor to the onset or aggravation of renal stone disease in the particular factual matrix and explains how the clinical evidence satisfies the instrument’s thresholds. Address potential issues such as latency calculations, cumulative exposure assessments, and alternative causes that the decision maker may consider.

8. Record keeping and contemporaneous documentation

• Given the precision of the time windows and thresholds, contemporaneous records are most persuasive. Where contemporaneous testing is lacking, provide reasoned explanation and alternative evidence such as long‑term clinical notes, GP records, and corroborative witness statements.

9. Review coding but follow the instrument’s textual definition

• While the instrument notes the usual ICD‑10‑AM code N20 applies to renal stone disease in practice (s7(3)), the statutory textual definition in s7(2) governs. Ensure documentation addresses the textual elements of location (kidney or ureter) and excludes conditions the Statement excludes.

10. Check for procedural and appellate pathways

• If a decision maker applies the Statement in a way that disputes arise about whether a factor is met or related to service, be ready to pursue the statutory review and appeal processes under the VEA or MRCA. Keep in mind the Statement does not create remedies; it supplies a standard for causation.

By methodically aligning documentary and expert evidence to the precise wording and numeric definitions in s9 and the Schedule, claimants and their advisers will position a claim to satisfy the "reasonable hypothesis" test the Statement supplies. In all cases preserve and present primary source materials that directly correspond to the instrument’s thresholds.